California fails to stop 23andMe founder from re-acquiring company

A U.S. Bankruptcy Judge has approved the $305 million sale of genetic testing firm 23andMe to co-founder Anne Wojcicki's TTAM Research, overriding objections from California and other states regarding the transfer of sensitive genetic data. The judge ruled that California's privacy-focused appeal was "likely to fail" and customers would not be "irreparably harmed," clearing the path for 23andMe to exit bankruptcy following a data breach and diminished consumer demand. This decision is significant as it allows a distressed asset sale involving millions of genetic profiles to proceed despite state-level privacy concerns, potentially influencing future transactions in the consumer health data sector.

Analysis

A U.S. Bankruptcy Court has cleared the path for genetic testing firm 23andMe to exit bankruptcy through a $305 million sale to co-founder Anne Wojcicki's non-profit, TTAM Research. The ruling is significant as it overrode strenuous objections from California, which argued the transfer of genetic data for its 1.8 million residents violated state privacy laws. The judge deemed the state's appeal "likely to fail," establishing a critical legal precedent that may prioritize the sale of distressed assets over state-level data privacy concerns, provided consumer rights like data deletion are maintained. This outcome is a strategic setback for Regeneron Pharmaceuticals (REGN), which was outbid after offering $265 million, signaling its strong interest in acquiring 23andMe's extensive database of approximately 10 million genetic profiles for research purposes. The entire bankruptcy proceeding, triggered by a 2023 data breach and declining consumer demand, underscores the volatile intersection of consumer data, privacy regulation, and corporate restructuring in the biotech sector.

Key Decisions for Investors

• For investors in Regeneron (REGN), the failure to acquire 23andMe's valuable genetic database represents a missed strategic opportunity to bolster its R&D capabilities, as the company was ultimately outbid in a competitive process.
• The court's approval of the data transfer despite state-level privacy objections sets a notable precedent, potentially lowering the perceived legal risk for future M&A targeting data-rich, distressed companies in the consumer health and biotech sectors.
• Investors should monitor the ongoing tension between aggressive state privacy legislation and federal bankruptcy court rulings, as this conflict could introduce headline risk and regulatory uncertainty for companies whose value is heavily tied to large consumer data sets.